Production (Stage)
Entrada Therapeutics, Inc.
TRDA
$7.59
-$0.26-3.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -45.03% | 91.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -45.03% | 91.10% | |||
| Cost of Revenue | -3.99% | 6.88% | |||
| Gross Profit | -388.48% | 134.16% | |||
| SG&A Expenses | 4.21% | -1.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.12% | 4.94% | |||
| Operating Income | -271.40% | 72.91% | |||
| Income Before Tax | -2,247.63% | 95.35% | |||
| Income Tax Expenses | -- | -0.54% | |||
| Earnings from Continuing Operations | -1,633.95% | 108.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,633.95% | 108.06% | |||
| EBIT | -271.40% | 72.91% | |||
| EBITDA | -327.57% | 76.47% | |||
| EPS Basic | -1,624.91% | 108.02% | |||
| Normalized Basic EPS | -2,236.28% | 95.38% | |||
| EPS Diluted | -2,160.49% | 105.86% | |||
| Normalized Diluted EPS | -2,367.29% | 95.62% | |||
| Average Basic Shares Outstanding | 0.57% | 0.52% | |||
| Average Diluted Shares Outstanding | -4.59% | 5.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||